Newronika develops an adaptive deep brain stimulation (αDBS) system for Parkinson’s patients that continuously monitors brain signals and automatically adjusts stimulation in real time. The platform combines a patented proportional control algorithm with the WebBioBank™ cloud‑based neural data platform, enabling remote patient monitoring and longitudinal biomarker analysis to reduce side effects and extend symptom relief. Clinical validation across Europe shows a 2.4× longer continuous relief compared with conventional DBS.
Funding
$14.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with Parkinson’s disease receiving conventional deep brain stimulation (DBS) experience fixed, unchanging stimulation that does not account for fluctuations in brain activity, medication cycles, or activity levels, leading to suboptimal symptom control and higher side‑effect risk.
Solution
Newronika’s αDBS system provides adaptive closed‑loop deep brain stimulation that continuously monitors neural biomarkers and automatically adjusts stimulation in real time. A patented proportional control algorithm linearly tracks α/β spectrum signals to maintain patients within their therapeutic window, reducing side effects and extending continuous symptom relief up to 2.4 × longer than standard DBS. Brain data are streamed to the cloud‑based WebBioBank™ platform, where AI‑driven analytics generate longitudinal neural records and support remote patient monitoring. Clinicians access an intuitive programming interface that integrates with existing workflows, enabling fewer office visits while preserving precise therapy personalization.
Target Audience
Primary customers are neurologists, movement‑disorder specialists, and DBS implant centers treating Parkinson’s disease patients who require advanced, adaptive neuromodulation.
Features
- Continuous minute‑by‑minute sensing of neural biomarkers across the full α/β spectrum
- Patented proportional control algorithm that linearly maps biomarker changes to stimulation intensity
- Real‑time closed‑loop adjustment of DBS parameters without manual clinician intervention
- Cloud‑based WebBioBank™ platform for secure storage, AI analysis, and longitudinal neural data aggregation
- Remote patient monitoring with automatic at‑home data transmission and clinician dashboard
- CE‑marked, clinically validated hardware designed for seamless integration into standard DBS surgical implants
- Streamlined programming interface that reduces configuration time and fits existing clinical workflows